Παρακαλώ χρησιμοποιήστε αυτό το αναγνωριστικό για να παραπέμψετε ή να δημιουργήσετε σύνδεσμο προς αυτό το τεκμήριο:
https://hdl.handle.net/20.500.14279/19277| Τίτλος: | Metoprolol and sertraline combined treatment may increase the risk of bradycardia | Συγγραφείς: | Protopapas, Andreas Lambrinou, Ekaterini |
Major Field of Science: | Medical and Health Sciences | Field Category: | Clinical Medicine | Λέξεις-κλειδιά: | Fluvoxamine;Mirtazapine;Norsertraline | Ημερομηνία Έκδοσης: | Οκτ-2020 | Πηγή: | Archives of Hellenic Medicine, 2020, vol. 37, no. 5, pp. 692-695 | Volume: | 37 | Issue: | 5 | Start page: | 692 | End page: | 695 | Link: | http://www.mednet.gr/archives/2020-5/pdf/692.pdf | Περιοδικό: | Archives of Hellenic Medicine | Περίληψη: | Patients with cardiovascular disease (CVD) commonly have anxiety and depressive disorders. They may need to take selective serotonin reuptake inhibitors (SSRIs) along with metoprolol, one of the most common drugs prescribed to patients with CVD. This is a case study of a 64-year-old woman who developed severe sinus bradycardia after taking metoprolol for the management of paroxysmal atrial fibrillation (AF) and sertraline treatment of depression symptoms. Despite the fact that sertraline is a weaker inhibitor of CYP2D6, it may increase the risk of severe bradycardia. Health professionals need to be aware of this possible interaction and conduct clinical monitoring of heart rate and electrocardiogram during combined treatment, and to encourage the patients to self-monitor for bradycardia. | URI: | https://hdl.handle.net/20.500.14279/19277 | ISSN: | 11053992 | Rights: | © Athens Medical Society Attribution-NonCommercial-NoDerivatives 4.0 International |
Type: | Article | Affiliation: | Cyprus University of Technology |
| Εμφανίζεται στις συλλογές: | Άρθρα/Articles |
CORE Recommender
Αυτό το τεκμήριο προστατεύεται από άδεια Άδεια Creative Commons
